ERBB2 and neoplasm: Our findings demonstrate that combining pre-immunization by HER2-expressing oHSV-1 with intratumoral oHSV-1 therapy triggers a robust antitumor humoral and cellular response in HER2(+) tumor models, leading to significant improvements in both local and systemic tumor control.